News Focus
News Focus
Followers 15
Posts 1612
Boards Moderated 1
Alias Born 09/07/2010

Re: alertmeipp post# 9172

Monday, 06/25/2012 9:06:04 AM

Monday, June 25, 2012 9:06:04 AM

Post# of 20689
I don't think one can draw any inference as to the strength of MNTA's IP from its having lost a challenge to TEVA's Copaxone patents before court in the Southern District of New York. It was a test of TEVA's patents only.

MNTA's test should come in the fall in the trial of its suit against Amphastar/Watson for infringement of MNTA's patents. Given MNTA's home court advantage in the Ampha case, where the judge has already granted MNTA a preliminary injunction, I'd guess that MNTA's odds are much higher, and that we'll see a favorable view of their IP emerge from that trial. As I see it, the recent modest run up in the MNTA stock price was a reasonable gamble that they'd win the New York case. I would think that its price should stay in the 13s for the next several months before starting to creep up in a similar manner as the Ampha verdict date approaches.

OT, but I'm looking forward to seeing what the SCOTUS does with Obamacare today....